| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种新的多肽——人F1F0 ATP合成酶亚基15和编码这种多肽的多核苷酸 | CN99119920.0 | 1999-10-29 | CN1302868A | 2001-07-11 | 毛裕民; 谢毅 |
| 本发明公开了一种新的多肽——人F1FOATP合成酶亚基15,编码此多肽的多核苷酸和经DNA重组技术产生这种多肽的方法。本发明还公开了此多肽用于治疗多种疾病的方法,尤其是能量代谢与物质代谢障碍性疾病如DOWN综合症、子宫内的生长迟缓、幼儿迟发性纤维原细胞腊样脂褐素病变、BATTEN病症、利伯氏病、Alzheimer氏病及其它碳水化合物代谢病、脂质代谢异常病、氨基酸代谢病、发育紊乱症,某些肿瘤,某些遗传性疾病、神经系统疾病、血液病及免疫系统疾病等。本发明还公开了抗此多肽的拮抗剂及其治疗作用。本发明还公开了编码这种新的人F1FOATP合成酶亚基15的多核苷酸的用途。 | ||||||
| 2 | Polypeptide to target the mitochondria | JP2008546588 | 2006-12-19 | JP2009520488A | 2009-05-28 | アーロン クラッグ，; モニカ エー． パプワース，; マイケル ミンクズク， |
| ミトコンドリアに非ミトコンドリアタンパク質を送達する方法が提供される。 また、ミトコンドリアターゲティング配列（ＭＴＳ）、核外移行シグナル（ＮＥＳ）およびコードされたタンパク質に融合されたＤＮＡ結合性ポリペプチドをコードするコード配列を含む核酸構築物も提供される。 前記構築物は、ミトコンドリアにＤＮＡ結合性タンパク質を正常に送達する。 上記の構築物に基づくキメラのメチラーゼはミトコンドリアに正常に送達され、それによってｍｔＤＮＡの改変がもたらされる。 | ||||||
| 3 | Angiostatin receptor | JP2000549284 | 1999-05-19 | JP2003527068A | 2003-09-16 | スタック、メアリー・エス; ピッゾ、サルバトーレ・ブイ; モーザー、タミー・エル |
| (57)【要約】 本発明は、一般に、アンジオスタチンレセプター、特に細胞形質膜に存在するアンジオスタチンレセプターに関する。 更に詳しくは、本発明は、ヒトアンジオスタチンレセプター、ＡＴＰシンターゼまたはそのサブユニット若しくはその一部分と、およびヒトアンジオスタチンのアゴニストまたはアンタゴニストとして使用できる能力について化合物をスクリーニングするために計画されたアッセイにおけるその使用とに関する。 更に、本発明は、ＡＴＰシンターゼまたはそのサブユニット若しくは一部分をコードする核酸配列、およびそれをもって形質転換されたホスト細胞に関する。 また、本発明は、ＡＴＰシンターゼに特異的な抗体に関する。 | ||||||
| 4 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | EP15799189.4 | 2015-05-27 | EP3148565A2 | 2017-04-05 | WILSON, D. Travis |
| Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2. | ||||||
| 5 | POLYPEPTIDE TARGETING TO MITOCHONDRIA | US14859596 | 2015-09-21 | US20160199443A1 | 2016-07-14 | Michal Minczuk; Monika A. Papworth; Aaron Klug |
| Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA. | ||||||
| 6 | Polypeptide targeting to mitochondria | US12143886 | 2008-06-23 | US09139628B2 | 2015-09-22 | Michal Minczuk; Monika A. Papworth; Aaron Klug |
| Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA. | ||||||
| 7 | MITOCHONDRIAL TARGETED RNA EXPRESSION SYSTEM AND USE THEREOF | US13860156 | 2013-04-10 | US20130274314A1 | 2013-10-17 | Michael J. Palladino; Alicia M. Palladino |
| Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | ||||||
| 8 | Control of Varroa mite infestation | US14902505 | 2014-07-02 | US09932590B2 | 2018-04-03 | Alan Stuart Bowman; Ewan McInnes Campbell; Giles Elliott Budge |
| Nucleic acid agents for reducing or removing infestations of the Varroa destructor mite are described. Compositions comprising the nucleic acid agents and methods for controlling mite infestations using the nucleic acid agents and compositions are also disclosed. | ||||||
| 9 | Modified live (JMSO strain) Haemophilus parasuis vaccine | US13385303 | 2012-02-13 | US09132183B2 | 2015-09-15 | Kamesh R. Sirigireddy; Paulraj K. Lawrence; Russell F. Bey; Randy R. Simonson |
| The present invention is a live vaccine from a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth. Several SNPs have been identified as associated with specific proteins that are associated with virulence as seen in the literature in H. parasuis or related bacterial species. | ||||||
| 10 | Mitochondrial targeted RNA expression system and use thereof | US13860156 | 2013-04-10 | US08883755B2 | 2014-11-11 | Michael J. Palladino; Alicia M. Palladino |
| Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | ||||||
| 11 | ENHANCED YEAST FERMENTATION PLATFORM USING YEAST LACKING MITOCHONDRIAL DNA AND CONTAINING GROWTH IMPROVING MUTATIONS | US14243410 | 2014-04-02 | US20140302577A1 | 2014-10-09 | Peter E. Thorsness; Christopher P. Smith |
| Methods for enhanced yeast fermentation of plant material through the genetic modification of non-respiring yeast are provided including the introduction of a dominant mitochondrial ATP synthase gene mutation into a non-respiring yeast that entirely lacks mitochondrial DNA and transgenic yeast for the enhanced yeast fermentation of plant material lacking mitochondrial DNA while having a dominant mitochondrial ATP synthase gene mutation in the nuclear genome. Methods further include the introduction of a mitochondrial genome into a non-respiring yeast lacking the COX1, COX2, COX3, or COB gene as well as transgenic yeast having a mitochondrial genome lacking the COX1, COX2, COX3, or COB gene. Additional methods include the creation of a disrupted copy of the CAT5 nuclear gene in a non-respiring yeast as well as transgenic yeast having a disrupted copy of the CAT5 nuclear gene are also disclosed. | ||||||
| 12 | Modulation of blood brain barrier protein expression | US12597458 | 2008-04-23 | US08466118B2 | 2013-06-18 | William A. Banks; Vijaya B. Kumar; Thomas Darling; Robert Clayton |
| There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered. | ||||||
| 13 | Angiostatin receptor | US10007698 | 2001-12-10 | US20030017512A1 | 2003-01-23 | Tammy L. Moser; Salvatore V. Pizzo; Mary S. Stack |
| The present invention relates, in general, to an angiostatin receptor and, in particular, to an angiostatin receptor present on cellular plasma membranes. More particularly, the present invention relates to the human angiostatin receptor, ATP synthase, or subunit or portion thereof, and to the use thereof in assays designed to screen compounds for their ability to serve as agonists or antagonists of human angiostatin. The invention further relates to nucleic acid sequences encoding ATP synthase, or subunit or portion thereof, and to host cells transformed therewith. The invention also relates to antibodies specific for ATP synthase. | ||||||
| 14 | Angiostatin receptor | US09314159 | 1999-05-19 | US06444431B1 | 2002-09-03 | Tammy L. Moser; Salvatore V. Pizzo; Mary S. Stack |
| The present invention relates, in general, to an angiostatin receptor and, in particular, to an angiostatin receptor present on cellular plasma membranes. More particularly, the present invention relates to the human angiostatin receptor, ATP synthase, or subunit or portion thereof, and to the use thereof in assays designed to screen compounds for their ability to serve as agonists or antagonists of human angiostatin. The invention further relates to nucleic acid sequences encoding ATP synthase, or subunit or portion thereof, and to host cells transformed therewith. The invention also relates to antibodies specific for ATP synthase. | ||||||
| 15 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | EP18210159.2 | 2015-05-27 | EP3501532A2 | 2019-06-26 | WILSON, D. Travis |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2. |
||||||
| 16 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | EP15799189 | 2015-05-27 | EP3148565A4 | 2018-06-06 | WILSON D TRAVIS |
| Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2. | ||||||
| 17 | ANGIOSTATIN RECEPTOR | EP99924316 | 1999-05-19 | EP1079848A4 | 2004-06-16 | STACK MARY S; MOSER TAMMY L; PIZZO SALVATORE V |
| 18 | CONTROL OF VARROA MITE INFESTATION | US14902505 | 2014-07-02 | US20160355823A1 | 2016-12-08 | Alan Stuart Bowman; Ewan Mclnnes Campbell; Giles Elliott Budge |
| Nucleic acid agents for reducing or removing infestations of the Varroa destructor mite are described. Compositions comprising the nucleic acid agents and methods for controlling mite infestations using the nucleic acid agents and compositions are also disclosed. | ||||||
| 19 | URINARY BIOMARKERS OF RENAL AND MITOCHONDRIAL DYSFUNCTION | US14471696 | 2014-08-28 | US20150064715A1 | 2015-03-05 | Rick SCHNELLMANN; John ARTHUR; Craig BEESON |
| The present invention provides methods of detecting mitochondrial dysfunction or acute kidney injury (AKI) by measuring the urinary protein levels of the ATP synthase (ATPS) beta subunit or cleavage products thereof in a subject. | ||||||
| 20 | MITOCHONDRIAL TARGETED RNA EXPRESSION SYSTEM AND USE THEREOF | US14511899 | 2014-10-10 | US20150038561A1 | 2015-02-05 | Michael J. Palladino; Alicia M. Palladino |
| Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | ||||||
QQ群二维码
意见反馈
意见反馈